Abstract

Estrogen receptor alpha (ERα) signaling has beneficial skeletal effects in males. ERα signaling also affects other tissues, and to find bone-specific treatments, more knowledge regarding tissue-specific ERα signaling is needed. ERα is subjected to posttranslational modifications, including phosphorylation, which can influence ERα function in a tissue-specific manner. To determine the importance of phosphorylation site S122 (corresponding to human ERα site S118) for the skeleton and other tissues, male mice with a S122A mutation were used. Total areal bone mineral density was similar between gonadal intact S122A and WT littermates followed up to 12 months of age, and weights of estrogen-responsive organs normalized for body weight were unchanged between S122A and WT males at both 3 and 12 months of age. Interestingly, 12-month-old S122A males had decreased body weight compared to WT. To investigate if site S122 affects the estrogen response in bone and other tissues, 12-week-old S122A and WT males were orchidectomized (orx) and treated with estradiol (E2) or placebo pellets for four weeks. E2 increased cortical thickness in tibia in both orx WT (+ 60%, p < 0.001) and S122A (+ 45%, p < 0.001) males. However, the E2 effect on cortical thickness was significantly decreased in orx S122A compared to WT mice (− 24%, p < 0.05). In contrast, E2 affected trabecular bone and organ weights similarly in orx S122A and WT males. Thus, ERα phosphorylation site S122 is required for a normal E2 response specifically in cortical bone in male mice, a finding that may have implications for development of future treatments against male osteoporosis.

Details

Title
Phosphorylation of S122 in ERα is important for the skeletal response to estrogen treatment in male mice
Author
Horkeby, Karin 1   VIAFID ORCID Logo  ; Farman, Helen H. 1 ; Movérare-Skrtic, Sofia 1 ; Lionikaite, Vikte 1 ; Wu, Jianyao 1 ; Henning, Petra 1 ; Windahl, Sara 2 ; Sjögren, Klara 1 ; Ohlsson, Claes 3 ; Lagerquist, Marie K. 1 

 Sahlgrenska Academy at University of Gothenburg, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at Institute of Medicine, Göteborg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582) 
 Sahlgrenska Academy at University of Gothenburg, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at Institute of Medicine, Göteborg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); Karolinska Institute, Division of Pathology, Department of Laboratory Medicine, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Sahlgrenska Academy at University of Gothenburg, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at Institute of Medicine, Göteborg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); Sahlgrenska University Hospital, Region Västra Götaland, Department of Drug Treatment, Gothenburg, Sweden (GRID:grid.1649.a) (ISNI:000000009445082X) 
Pages
22449
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2758461721
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.